STEBVax is under clinical development by Integrated BioTherapeutics and currently in Phase I for Staphylococcus aureus Infections. According to GlobalData, Phase I drugs for Staphylococcus aureus Infections have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STEBVax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STEBVax overview
STEBVax is under development for the prevention of toxic shock syndrome from staphylococcus enterotoxin B. It is administered intramuscularly. STEBVax is a proprietary, rationally designed and attenuated form of staphylococcal enterotoxin B (SEB) vaccine. Staphylococcal enterotoxin B (SEB) is a selected agent because it is a mitogen that elicits polyclonal T-cell proliferation and cytokine production at very low concentrations.
Integrated BioTherapeutics overview
Integrated BioTherapeutics (IBT) is a biotechnology company that discovers novel vaccines and therapeutics for infectious diseases. The company’s products comprise polyclonal and monoclonal antibodies raised against emerging pathogens, vaccines and therapeutics against bacteria, pan-filovirus antibody candidates, vaccines and a variety of other product candidates for antiviral diseases. It also provides research and development service such as vaccine immunogenicity and efficacy testing, antiviral testing, assay development, antibiotic testing, animal model testing and cytokine and biomarker analysis services. IBT’s vaccines and antibody therapeutics are used in the treatment of Filoviruses Ebola, Hemorrhagic fevers, Marbur, Sudan, Equine Encephalitis viruses and Chikungunya and Hepatitis C. The company partners with biotechnology, pharmaceutical, and academic laboratories. IBT is headquartered in Rockville, Maryland, the US.
For a complete picture of STEBVax’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
